Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Epagny Metz Tessy

48 clinical trials in Epagny Metz Tessy, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Epagny Metz Tessy at a glance
48
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

48 trials in Epagny Metz Tessy

Open in trial search

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Chronic obstructive pulmonary disease

Recruiting

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Systemic scleroderma

Recruiting

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Prophylaxis of nausea and vomiting+1

Recruiting

A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Aprepitant
  • Sponsor:Eli Lilly & Co.

Plasma cell myeloma

Recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Chronic obstructive pulmonary disease

Recruiting

Long-term Safety Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease and History of Exacerbations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Epagny Metz Tessy

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple myeloma treatments, exploring new therapeutic combinations and maintenance strategies. Studies include evaluations of esophageal squamous cell carcinoma and advanced approaches for triple-negative breast cancer.

  • Multiple Myeloma Treatments
  • Esophageal Cancer Therapy
  • Breast Cancer Management

Several trials are investigating immunotherapy combinations and targeted treatments for various cancer types.

02 Cardiovascular Studies

Research focusing on innovative approaches to treat patients with atrial fibrillation post-coronary intervention, and new protocols for managing acute ischemic stroke.

  • Anticoagulation Strategies
  • Stroke Prevention
  • Post-PCI Management

Trials aim to optimize antithrombotic treatments and improve patient outcomes.

03 Immunology and Infectious Diseases

Studies evaluating treatments for granulomatosis with polyangiitis and investigating novel approaches to prosthetic joint infections. Important research on pneumococcal vaccine effectiveness in high-risk populations.

  • Autoimmune Conditions
  • Infection Management
  • Vaccine Studies

Focus on developing more effective treatments for both acute and chronic conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.